Phase I trial finds topical PXS-6302 generally well tolerated in established skin scars

Published Date: 13 Sep 2025

University of Western Australia's Burn Injury Research Unit with the Fiona Wood Foundation reports that topical pan-lysyl oxidase inhibition with PXS-6302 was generally well tolerated over three months and altered extracellular ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

3.

Taking vitamin D daily decreased cancer mortality, according to a study.

4.

Study reveals increase in late-stage breast cancer diagnoses in US

5.

Prostate cancer Q&A: Improving detection and reducing overtreatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot